Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome

Hypertension

Volumn 59, Issue 3, 2012, Pages 719-725

  Smith, James P ^a   Haddad, Elias V ^a   Taylor, Mary B ^a   Oram, Denise ^a   Blakemore, Dana ^a   Chen, Qingxia ^a   Boutaud, Olivier ^b   Oates, John A ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aspirin; coronary disease; metabolic syndrome; platelets; thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE FUNCTION;

AGED; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLATELET AGGREGATION; PROSPECTIVE STUDIES; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 84862777870     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.181404     Document Type: Article

References (46)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
3. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects-the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S-264S. (Pubitemid 39297956)
4. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975;72:2994-2998.
5. Bala M, Chin CN, Logan AT, Amin T, Marnett LJ, Boutaud O, Oates JA. Acetylation of prostaglandin h2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol. 2008;75:1472-1481.
6. Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance." J Am Coll Cardiol. 2009;53:667-677.
7. Bridges JM, Dalby AM, Millar JH, Weaver JA. An effect of D-glucose on platelet stickiness. Lancet. 1965;1:75-77.
8. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med. 1990;322:1769-1774. (Pubitemid 20194655)
9. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA. 2002;288:2008-2014. (Pubitemid 35204691)
10. Kubisz P, Arabi A, Seghier F, Cronberg S. Investigations on the effect of thrombocytin on platelets. Thromb Res. 1984;33:225-227.
11. McDonagh PF, Hokama JY, Gale SC, Logan JJ, Davis-Gorman G, Goldman S, Copeland JG. Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: chronic platelet activation in diabetic heart patients. J Diabetes Complications. 2003;17:269-278. (Pubitemid 37040774)
12. Trovati M, Anfossi G. Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus. Curr Diab Rep. 2002;2:316-322.
13. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L. Factors associated with oxidative stress in human populations. Am J Epidemiol. 2002;156:274-285. (Pubitemid 34810481)
14. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434-439. (Pubitemid 36337219)
15. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211-218.
16. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37:2153-2158. (Pubitemid 44309919)
17. Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120:2586-2596.
18. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46: 1258-1263. (Pubitemid 41615546)
19. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am. 2004;33:333-350. (Pubitemid 38680633)
20. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-414. (Pubitemid 46135879)
21. Roberts LJ, II, Sweetman BJ, Oates JA. Metabolism of thromboxane b2 in man: identification of twenty urinary metabolites. J Biol Chem. 1981; 256:8384-8393. (Pubitemid 12254787)
22. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655. (Pubitemid 34298607)
23. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase- 2 to elevated biosynthesis of thromboxane a2 and prostacyclin in cigarette smokers. Circulation. 2005;112:1024-1029. (Pubitemid 41170271)
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-2752. (Pubitemid 41532612)
25. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane b2 production in healthy subjects. Thromb Res. 1980;17:317-327. (Pubitemid 10129020)
26. Parsons WG III, Roberts LJ II. Transformation of prostaglandin d2 to isomeric prostaglandin f2 compounds by human eosinophils: a potential mast cell-eosinophil interaction. J Immunol. 1988;141:2413-2419.
27. Morrow JD, Minton TA. Improved assay for the quantification of 11-dehydrothromboxane b2 by gas chromatography-mass spectrometry. J Chromatogr. 1993;612:179-185. (Pubitemid 23067174)
28. 2+) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest. 2008;118:2121-2131. (Pubitemid 351872331)
29. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-186. (Pubitemid 17007095)
30. Serebruany VL, Malinin A, Ong S, Atar D. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. J Thromb Thrombolysis. 2008;25: 207-213. (Pubitemid 351595984)
31. Vaduganathan M, Alviar CL, Arikan ME, Tellez A, Guthikonda S, DeLao T, Granada JF, Kleiman NS, Ballantyne CM, Lev EI. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008;156:1002 e1001-1002 e1007.
32. Vaidya D, Yanek LR, Faraday N, Moy TF, Becker LC, Becker DM. Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. Metab Syndr Relat Disord. 2009;7:289-296.
33. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, Jimenez JJ, Mendez A, Ferreira A, de Marchena E, Ahn YS. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol. 2006;98:70-74. (Pubitemid 43902682)
34. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble p-selectin and cd40l levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome: the Chennai Urban Rural Epidemiology Study. Metabolism. 2006;55:237-242. (Pubitemid 43098993)
35. Natal C, Restituto P, Inigo C, Colina I, Diez J, Varo N. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab. 2008;93: 2319-2327. (Pubitemid 351831554)
36. Jesri A, Okonofua EC, Egan BM. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. J Clin Hypertens (Greenwich). 2005 7:705-711, quiz 712-703.
37. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-2141.
38. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011;106:491-499.
39. Cagirci G, Ozdemir O, Geyik B, Cay S, Ozturk S, Aras D, Topaloglu S. The prevalence of aspirin resistance in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2009;37:461-466.
40. Kahraman G, Sahin T, Kilic T, Baytugan NZ, Agacdiken A, Ural E, Ural D, Komsuoglu B. The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol. 2007;115:391-396. (Pubitemid 46188589)
41. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, Michelson AD. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008;6:2035-2044.
42. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-965. (Pubitemid 36315537)
43. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
44. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195-198. (Pubitemid 351212675)
45. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, Tello- Montoliu A, Desai B, Bass TA, Angiolillo DJ. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv. 2011;4:180-187.
46. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ II, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688. (Pubitemid 13160815)